• Mashup Score: 0

    DENVER — A varied and well-balanced diet plays “a significant role” in the management of patients with inflammatory bowel disease and can be guided with support from a dietitian, a presenter reported at the Crohn’s and Colitis Congress.“IBD has long been thought to arise from inappropriate and maladaptive stimulation of the immune system, although emerging data has

    Tweet Tweets with this article
    • #ICYMI: “We should encourage our #patients to consume a varied and well-balanced #diet," Keisa M. Lynch, DNP, APRN, FNP, said at #CCCongress23. #GITwitter #MedTwitter #IBD https://t.co/5deHfGU1Lv

  • Mashup Score: 0

    DENVER — A risk stratification assessment assisted both patients with Crohn’s disease and their physicians when making decisions about treatment, according to data presented at the Crohn’s and Colitis Congress. Earlier introduction of advanced therapy may improve longer-term clinical outcomes in CD, with current clinical guidelines recommending the incorporation of risk

    Tweet Tweets with this article
    • #ICYMI from #CCCongress23: @AmerGastroAssn risk assessment tool aids #patient, #physician decision-making for #Crohns therapy @ryanungaro #GITwitter #MedTwitter https://t.co/lQ0w2y0Z0m

  • Mashup Score: 0

    DENVER — Although the use of artificial intelligence for inflammatory bowel disease can reasonably replicate expert judgment and predict outcomes, clinicians must retain the ability to intervene and “take control” when the AI is wrong.“I don’t have to tell any of you that artificial intelligence is everywhere right now, doing some truly amazing tasks and starting to

    Tweet Tweets with this article
    • “I think that if we use #AI in the right ways, we can not only preserve but improve the #patient-#caregiver relationship, because AI is going to give us back a lot of time so that we can do what we love doing," @CrohnsDoc said at #CCCongress23 #GITwitter https://t.co/qOQpkz2QaM

  • Mashup Score: 0

    DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.“We have all these different mechanisms of action right now — in newer development are some of the oral and p-19 [inhibitors],” Edward V. Loftus

    Tweet Tweets with this article
    • ‘Why not combine them," @EdwardLoftus2 said at #CCCongress23. Early dual #biologic therapy may overcome limits in severe #IBD. #GITwitter #MedTwitter https://t.co/RqnadklkZq

  • Mashup Score: 2

    DENVER — In a Healio video exclusive, James D. Lewis, MD, MSCE, a gastroenterologist at the University of Pennsylvania Perelman School of Medicine, discusses what it might take to eventually cure or prevent inflammatory bowel disease.According to Lewis, there has been “incredible” progress in IBD management over the past several decades with the expansion of new biologic

    Tweet Tweets with this article
    • In a @GoHealio #GI video exclusive, @JamesLewisGIEpi discusses what it might take to eventually #cure or #prevent #IBD. #CCCongress23 #GITwitter #MedTwitter https://t.co/9auGOb58Wt

  • Mashup Score: 1

    DENVER — Hyperbaric oxygen therapy yielded a clinical response rate of 87% among patients with fistulizing Crohn’s disease with few adverse events, according to systematic review data presented at the Crohn’s and Colitis Congress.“Fistulas are a common complication of Crohn’s disease occurring in up to 50% of patients,” Amr Dokmak, MD, a hospitalist at Catholic

    Tweet Tweets with this article
    • #ICYMI from #CCCongress23: “Hyperbaric #oxygen therapy is a safe and potentially effective treatment option for fistulizing #Crohnsdisease,” @amrdokmak told @GoHealio #GI #GITwitter #MedTwitter #IBD https://t.co/j16CYP6YLO

  • Mashup Score: 0

    DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.“We have all these different mechanisms of action right now — in newer development are some of the oral and p-19 [inhibitors],” Edward V. Loftus

    Tweet Tweets with this article
    • Early data suggest combination therapy with #biologics or advanced small-molecules may be safe and effective in patients with #IBD, according to a presenter at #CCCongress23; @EdwardLoftus2 said, “we have all these different targets: Why not combine them?” https://t.co/RqnadklkZq

  • Mashup Score: 0

    DENVER — Socioeconomic status, household composition and housing or transportation were among predictors of low vaccination rates in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress. “Despite an increased risk for infection, patients with IBD have low vaccination rates,” Jessica Sheehan, MD, a gastroenterology and

    Tweet Tweets with this article
    • #ICYMI from #CCCongress23: Patients with ##IBD in ‘socially vulnerable’ communities less likely to be #vaccinated @JessSheehanMD #GITwitter #MedTwitter https://t.co/AFpCUmtG4B